Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Delivery
Philip Morris adds to pharma unit with acquisition of inhaled-drug firm OtiTopic
by Megha Satyanarayana
August 19, 2021
| A version of this story appeared in
Volume 99, Issue 30
Philip Morris International continues its push into drug delivery with the acquisition of OtiTopic, a Los Angeles–based specialist in inhaled drugs. OtiTopic has an inhalable acetylsalicylic acid treatment called Asprihale in late-stage trials for myocardial infarction. Philip Morris recently announced deals to buy the drug delivery firms Fertin Pharma and Vectura Group for a combined $2 billion. The cigarette company says the acquisitions are part of its Beyond Nicotine diversification strategy.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X